G613 | CAS#unknown | Anti-cancer

MedKoo Cat#: 208244 | Name: G613

Description:

WARNING: This product is for research use only, not for human or veterinary use.

G613 has shown growth inhibitory activity in breast cancer cells. Additionally, the compound decreased estrogen receptor activity through sequestration of estrogen receptor α by p53 thereby causing a decreased transcriptional activation and expression of proliferation markers. In conclusion, G613 represents a potent small-molecule inhibitor of the Mdm2-p53 interaction and can serve as a promising lead for developing a new class of anti-cancer therapy for breast cancer patients.

Chemical Structure

G613

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 208244

Name: G613

CAS#: unknown

Chemical Formula: C36H34ClN3O4

Exact Mass: 607.2238

Molecular Weight: 607.14

Elemental Analysis: C, 71.10; H, 5.64; Cl, 5.83; N, 6.91; O, 10.52

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

G-613, G6-13, G61-3

IUPAC/Chemical Name

5-Chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one

InChi Key

QPWWUAQNASGKKV-LABVJWKOSA-N

InChi Code

InChI=1S/C36H34ClN3O4/c37-27-13-16-29-30(23-27)38-35(42)36(29)32(31(24-7-3-1-4-8-24)33(39-36)25-9-5-2-6-10-25)34(41)26-11-14-28(15-12-26)44-22-19-40-17-20-43-21-18-40/h1-16,23,31-33,39H,17-22H2,(H,38,42)/t31-,32+,33+,36-/m0/s1

SMILES Code

O=C1NC2=C([C@]31N[C@H](C4=CC=CC=C4)[C@@H](C5=CC=CC=C5)[C@@H]3C(C6=CC=C(OCCN7CCOCC7)C=C6)=O)C=CC(Cl)=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 607.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Saxena R, Gupta G, Manohar M, Debnath U, Popli P, Prabhakar YS, Konwar R, Kumar S, Kumar A, Dwivedi A. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function. Int J Biochem Cell Biol. 2016 Jan;70:105-17. doi: 10.1016/j.biocel.2015.11.003. Epub 2015 Nov 7. PMID: 26556313. 2: Krüger L, Pridgen TA, Taylor ER, Garman KS, Blikslager AT. Lubiprostone protects esophageal mucosa from acid injury in porcine esophagus. Am J Physiol Gastrointest Liver Physiol. 2020 Apr 1;318(4):G613-G623. doi: 10.1152/ajpgi.00086.2019. Epub 2020 Feb 18. PMID: 32068440; PMCID: PMC7191458. 3: Floccari LV, Jeans KA, Herring JA, Johnston CE, Karol LA. Comparison of Outcomes by Reconstructive Strategy in Patients with Prostheses for Proximal Femoral Focal Deficiency. J Bone Joint Surg Am. 2021 Oct 6;103(19):1817-1825. doi: 10.2106/JBJS.20.02001. PMID: 34270496. 4: Van Klinken BJ, Dekker J, Büller HA, Einerhand AW. Mucin gene structure and expression: protection vs. adhesion. Am J Physiol. 1995 Nov;269(5 Pt 1):G613-27. doi: 10.1152/ajpgi.1995.269.5.G613. PMID: 7491952. 5: Mao Y, Zhang Z, Wong B. Use of green fluorescent protein fusions to analyse the N- and C-terminal signal peptides of GPI-anchored cell wall proteins in Candida albicans. Mol Microbiol. 2003 Dec;50(5):1617-28. doi: 10.1046/j.1365-2958.2003.03794.x. PMID: 14651643. 6: Kizu T, Yoshida Y, Furuta K, Ogura S, Egawa M, Chatani N, Hamano M, Takemura T, Ezaki H, Kamada Y, Nishida K, Nakaoka Y, Kiso S, Takehara T. Loss of Gab1 adaptor protein in hepatocytes aggravates experimental liver fibrosis in mice. Am J Physiol Gastrointest Liver Physiol. 2015 Apr 1;308(7):G613-24. doi: 10.1152/ajpgi.00289.2014. Epub 2015 Jan 23. PMID: 25617348. 7: Meir M, Flemming S, Burkard N, Bergauer L, Metzger M, Germer CT, Schlegel N. Glial cell line-derived neurotrophic factor promotes barrier maturation and wound healing in intestinal epithelial cells in vitro. Am J Physiol Gastrointest Liver Physiol. 2015 Oct 15;309(8):G613-24. doi: 10.1152/ajpgi.00357.2014. Epub 2015 Aug 20. PMID: 26294673. 8: Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G613-26. doi: 10.1152/ajpgi.00341.2003. PMID: 15010363. 9: Donadio-Moura J, Gouw-Soares S, de Freitas PM, Navarro RS, Powell LG, Eduardo Cde P. Tensile bond strength of a flowable composite resin to ER:YAG-laser- treated dentin. Lasers Surg Med. 2005 Jun;36(5):351-5. doi: 10.1002/lsm.20176. PMID: 15825207. 10: Ewart WR, Wingate DL. Cholecystokinin octapeptide and gastric mechanoreceptor activity in rat brain. Am J Physiol. 1983 Jun;244(6):G613-7. doi: 10.1152/ajpgi.1983.244.6.G613. PMID: 6305211.